Turkish Journal of Hematology最新文献

筛选
英文 中文
Extreme Phenotypic Variation in Siblings with Identical Homozygous Mutations Causing ADA2 Deficiency: A Case Series 同卵同型突变导致 ADA2 缺乏症的兄弟姐妹中的极端表型变异:病例系列
IF 1.5 4区 医学
Turkish Journal of Hematology Pub Date : 2025-02-28 Epub Date: 2025-01-07 DOI: 10.4274/tjh.galenos.2025.2024.0373
Muhammed D Aksu, Seza Özen, Tekin Aksu, Ayşe Gürel, Arda Çetinkaya, Şule Ünal
{"title":"Extreme Phenotypic Variation in Siblings with Identical Homozygous Mutations Causing ADA2 Deficiency: A Case Series","authors":"Muhammed D Aksu, Seza Özen, Tekin Aksu, Ayşe Gürel, Arda Çetinkaya, Şule Ünal","doi":"10.4274/tjh.galenos.2025.2024.0373","DOIUrl":"10.4274/tjh.galenos.2025.2024.0373","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":"42 1","pages":"61-64"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antifungal Prophylaxis in the Treatment Combination of Hypomethylating Agents and Venetoclax for AML: A Survey Study of the Turkish Society of Hematology Subcommittee on Infections and Supportive Therapies in Hematology 低甲基化药物Venetoclax联合在aml中的抗真菌预防-土耳其血液学学会血液学感染和支持治疗小组委员会调查研究。
IF 1.5 4区 医学
Turkish Journal of Hematology Pub Date : 2025-02-28 Epub Date: 2024-12-25 DOI: 10.4274/tjh.galenos.2024.2024.0436
Tuğcan Alp Kırkızlar, Vildan Özkocaman
{"title":"Antifungal Prophylaxis in the Treatment Combination of Hypomethylating Agents and Venetoclax for AML: A Survey Study of the Turkish Society of Hematology Subcommittee on Infections and Supportive Therapies in Hematology","authors":"Tuğcan Alp Kırkızlar, Vildan Özkocaman","doi":"10.4274/tjh.galenos.2024.2024.0436","DOIUrl":"10.4274/tjh.galenos.2024.2024.0436","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"69-71"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Duplication of the Long Arm of Chromosome 3 Leads to MECOM Rearrangement in Acute Myeloid Leukemia 两条3号染色体长臂的重复导致急性髓系白血病MECOM重排。
IF 1.5 4区 医学
Turkish Journal of Hematology Pub Date : 2025-02-28 Epub Date: 2024-12-19 DOI: 10.4274/tjh.galenos.2024.2024.0395
Shaobin Yang, Shiyang Ma, Xiaoyan Yan, Jingya Yao, Yani Lin
{"title":"Duplication of the Long Arm of Chromosome 3 Leads to <i>MECOM</i> Rearrangement in Acute Myeloid Leukemia","authors":"Shaobin Yang, Shiyang Ma, Xiaoyan Yan, Jingya Yao, Yani Lin","doi":"10.4274/tjh.galenos.2024.2024.0395","DOIUrl":"10.4274/tjh.galenos.2024.2024.0395","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"56-58"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MiR-379-5p Inhibited the Proliferation of Acute Myeloid Leukemia Cells Through Negative Regulation of YBX1.
IF 1.5 4区 医学
Turkish Journal of Hematology Pub Date : 2025-02-24 DOI: 10.4274/tjh.galenos.2025.2024.0424
Huichao Wu, Lin Zhao, Huanyu Guo, Yingjie Xie, Jianhua Hu, Xinxia Tan
{"title":"MiR-379-5p Inhibited the Proliferation of Acute Myeloid Leukemia Cells Through Negative Regulation of YBX1.","authors":"Huichao Wu, Lin Zhao, Huanyu Guo, Yingjie Xie, Jianhua Hu, Xinxia Tan","doi":"10.4274/tjh.galenos.2025.2024.0424","DOIUrl":"https://doi.org/10.4274/tjh.galenos.2025.2024.0424","url":null,"abstract":"<p><strong>Objectives: </strong>Acute myeloid leukemia (AML) is a frequent and highly lethal hematological malignancy that is difficult to treat. The research aimed to clarify the molecular mechanisms of MIR-379-5p in AML progression.</p><p><strong>Materials and methods: </strong>RT-qPCR was utilized to evaluate MIR-379-5p expression levels in AML patients and a control group. A ROC curve was created to assess the clinical predictive value of MIR-379-5p in AML, while cell experiments used CCK-8 assay, flow cytometry, and Transwell chambers. Predicted potential target genes of MIR-379-5p by employing online bioinformatics tools, followed by validation using a dual luciferase reporter assay.</p><p><strong>Results: </strong>MIR-379-5p was significantly decreased in AML patients and had clinical predictive value for the disease. In AML cell lines, MIR-379-5p was down-regulated; conversely, the up-regulation of MIR-379-5p inhibited proliferation, migration, and invasion while promoting apoptosis. Notably, YBX1 was a potential target gene of MIR-379-5p, and its upregulation reduced the effects of MIR-379-5p on AML cell behavior.</p><p><strong>Conclusion: </strong>MIR-379-5p had the potential as a biomarker for AML by regulating cell proliferation and apoptosis through targeting YBX1.</p>","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decoding Cytoplasmic Vacuolization: Unravelling the Diagnostic Challenges of Vexas Syndrome.
IF 1.5 4区 医学
Turkish Journal of Hematology Pub Date : 2025-02-17 DOI: 10.4274/tjh.galenos.2025.2024.0444
Taner Tan, Mustafa Cem Bülbül, Merve Kaysin, İbrahim Öner Doğan, Olga Meltem Akay, Sinem Cıvrız Bozdağ
{"title":"Decoding Cytoplasmic Vacuolization: Unravelling the Diagnostic Challenges of Vexas Syndrome.","authors":"Taner Tan, Mustafa Cem Bülbül, Merve Kaysin, İbrahim Öner Doğan, Olga Meltem Akay, Sinem Cıvrız Bozdağ","doi":"10.4274/tjh.galenos.2025.2024.0444","DOIUrl":"https://doi.org/10.4274/tjh.galenos.2025.2024.0444","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The IRF2-INPP4B pathway is activated in CD4+ T cells and aggravates acute myeloid leukemia development by inhibiting apoptosis.
IF 1.5 4区 医学
Turkish Journal of Hematology Pub Date : 2025-02-17 DOI: 10.4274/tjh.galenos.2024.2025.0292
Xiangqin Xing, Mei Zhang, Shengfen Tan, Junfeng Zhu, Jiajia Li, Pingping Zhang, Yuan Yuan, Meng Wang, Feng Zhang
{"title":"The IRF2-INPP4B pathway is activated in CD4+ T cells and aggravates acute myeloid leukemia development by inhibiting apoptosis.","authors":"Xiangqin Xing, Mei Zhang, Shengfen Tan, Junfeng Zhu, Jiajia Li, Pingping Zhang, Yuan Yuan, Meng Wang, Feng Zhang","doi":"10.4274/tjh.galenos.2024.2025.0292","DOIUrl":"https://doi.org/10.4274/tjh.galenos.2024.2025.0292","url":null,"abstract":"<p><strong>Background: </strong>Interferon-regulatory factor 2 (IRF2)/inositol polyphosphate 4-phosphatase B (INPP4B) is essential for the differentiation of immune T cells. However, the regulatory mechanism of IRF2/INPP4B signaling pathway on apoptosis of acute myeloid leukemia (AML) cells remains unclear. Thus, this study intended to investigate the function and mechanism of IRF2/INPP4B in the development of AML.</p><p><strong>Methods: </strong>CD4+ T cells were isolated from peripheral blood and identified using flow cytometry. Apoptosis of AML cell line HL60 and the ration of Th1/Th2 were analyzed by flow cytometry. The mRNA expression of IRF2 was detected by quantitative real-time PCR method. Western blot was used to detect the protein accumulation of IRF2, INPP4B, JAK2, p-JAK2, STAT3, p-STAT3, and caspase 3. The contents of IL-4 and IFN-γ were measured by enzyme-linked immunosorbent assay (ELISA) kits.</p><p><strong>Results: </strong>We found that IRF2 and INPP4B were highly expressed in AML-derived CD4+ T cells. Further results indicated that CD4+ T cells promoted HL60 cell apoptosis. Moreover, we found that downregulation of IRF2 promoted HL60 cell apoptosis by regulating Th1/Th2 ratio. In addition, we revealed that overexpression of IRF2 activated JAK2/STAT3 signaling pathway and downregulated caspase 3 expression.</p><p><strong>Conclusion: </strong>We demonstrated that the IRF2-INPP4B signaling in CD4+ T cells activated the JAK2/STAT3 signaling pathway and downregulated caspase 3 expression, causing inhibition on AML cell apoptosis to aggravate AML development. This study proposes a novel regulatory mechanism in AML development, suggesting that the IRF2/INPP4B pathway might influence the JAK2-STAT3 signaling pathway, adding a new layer to our understanding of the complex interplay of these pathways in AML development.</p>","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis 蛋白酶体抑制剂和免疫调节药物时代原发性浆细胞白血病患者的生存结果:多中心实际分析
IF 1.5 4区 医学
Turkish Journal of Hematology Pub Date : 2024-12-02 Epub Date: 2024-11-06 DOI: 10.4274/tjh.galenos.2024.2023.0450
Ünal Ataş, Ozan Salim, Utku Iltar, Orhan Kemal Yücel, Ayşe Hilal Küçükdiler Eroğlu, Vedat Aslan, Murat Yıldırım, Özen Dedeoğlu, Sema Seçilmiş, Turgay Ulaş, Burak Deveci, Sedanur Karaman Gulsaran, Ayfer Gedük, Fatih Yaman, İbrahim Ethem Pınar, Senem Maral, Ahmet Sarıcı, Serhat Çelik, Hande Oğul, Sıdıka Gülkan Özkan, Aliihsan Gemici, Ahmet Kurşat Güneş, Anil Tombak, İrfan Yavaşoğlu, Volkan Karakuş, Melda Cömert, Tayfur Toptaş, Mehmet Sinan Dal, Rabin Saba, Hakkı Onur Kırkızlar, Özgür Mehtap, Eren Gündüz, Fahir Özkalemkaş, Murat Albayrak, İlhami Berber, Muzaffer Keklik, Nil Güler, Hasan Atilla Özkan, Ömür Gökmen Sevindik, Zahit Bolaman, Erdal Kurtoğlu, Meltem Aylı, Tülin Fıratlı Tuğlular, Fevzi Altuntaş, Levent Ündar
{"title":"Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis","authors":"Ünal Ataş, Ozan Salim, Utku Iltar, Orhan Kemal Yücel, Ayşe Hilal Küçükdiler Eroğlu, Vedat Aslan, Murat Yıldırım, Özen Dedeoğlu, Sema Seçilmiş, Turgay Ulaş, Burak Deveci, Sedanur Karaman Gulsaran, Ayfer Gedük, Fatih Yaman, İbrahim Ethem Pınar, Senem Maral, Ahmet Sarıcı, Serhat Çelik, Hande Oğul, Sıdıka Gülkan Özkan, Aliihsan Gemici, Ahmet Kurşat Güneş, Anil Tombak, İrfan Yavaşoğlu, Volkan Karakuş, Melda Cömert, Tayfur Toptaş, Mehmet Sinan Dal, Rabin Saba, Hakkı Onur Kırkızlar, Özgür Mehtap, Eren Gündüz, Fahir Özkalemkaş, Murat Albayrak, İlhami Berber, Muzaffer Keklik, Nil Güler, Hasan Atilla Özkan, Ömür Gökmen Sevindik, Zahit Bolaman, Erdal Kurtoğlu, Meltem Aylı, Tülin Fıratlı Tuğlular, Fevzi Altuntaş, Levent Ündar","doi":"10.4274/tjh.galenos.2024.2023.0450","DOIUrl":"10.4274/tjh.galenos.2024.2023.0450","url":null,"abstract":"<p><strong>Objective: </strong>In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma cell leukemia (pPCL) patients with poor prognosis.</p><p><strong>Materials and methods: </strong>Data from 53 patients who were diagnosed with pPCL between 2011 and 2020 and who used at least one proteasome inhibitor (PI) and/or immunomodulatory (IMID) agent were analyzed retrospectively. Depending on the year of the pPCL diagnosis, 20% leukocytes or ≥2x10<sup>9</sup>/L plasma cells in the peripheral blood was used as a diagnostic criterion.</p><p><strong>Results: </strong>The median age of the patients was 58 years and 23 (43.4%) patients were over 65 years of age. For first-line treatment, PI or IMID alone was used by 31 (58.5%) patients, and PI and IMID were used simultaneously by 15 (28.3%) patients. Additionally, 21 (39.6%) patients received transplantation and 13 (24.5%) patients received maintenance treatment. The median progression-free survival was 4 (range: 1-42) months. When patients whose primary disease was refractory to first-line therapy were excluded, the duration of treatment was 6.5 months. The median OS was 15 months with a median follow-up duration of 15 months. Only 7 (13.2%) of the patients were alive at the last follow-up visit. Those with higher β2-microglobulin levels and International Staging System stage 3 and non-transplant patients receiving first-line treatment had shorter OS (p=0.005, p=0.02, and p=0.008, respectively). The concomitant use of PIs and IMIDs, the addition of chemotherapy to induction therapy, and the response to induction therapy or maintenance therapy did not affect OS.</p><p><strong>Conclusion: </strong>In this study, as in previous similar studies, we could not see an increased survival trend in pPCL, which is observed in MM. New studies are needed for pPCL, which is likely to increase with new diagnostic criteria, based on current agents and information from MM.</p>","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"225-235"},"PeriodicalIF":1.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eosinophilia with STAT5BN642H Mutation: A Heterogeneous Entity with Overlapping Morphological Features and Poor Outcome 嗜酸性粒细胞增多伴 STAT5BN642H 基因突变:形态特征重叠且预后不佳的异质性实体
IF 1.5 4区 医学
Turkish Journal of Hematology Pub Date : 2024-12-02 Epub Date: 2024-08-29 DOI: 10.4274/tjh.galenos.2024.2024.0204
Venkat Shashidhar, Aishwarya Karthikeyan, Anand Balakrishnan, Sudhanshi Raina, Jasmina Ahluwalia, Reena Das, Pankaj Malhotra, Sreejesh Sreedharanunni
{"title":"Eosinophilia with <i>STAT5B</i>N642H Mutation: A Heterogeneous Entity with Overlapping Morphological Features and Poor Outcome","authors":"Venkat Shashidhar, Aishwarya Karthikeyan, Anand Balakrishnan, Sudhanshi Raina, Jasmina Ahluwalia, Reena Das, Pankaj Malhotra, Sreejesh Sreedharanunni","doi":"10.4274/tjh.galenos.2024.2024.0204","DOIUrl":"10.4274/tjh.galenos.2024.2024.0204","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"275-278"},"PeriodicalIF":1.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case of Rapidly Progressing Tumoral-Stage Mycosis Fungoides 一例进展迅速的真菌病瘤期病例
IF 1.5 4区 医学
Turkish Journal of Hematology Pub Date : 2024-12-02 Epub Date: 2024-11-18 DOI: 10.4274/tjh.galenos.2024.2024.0298
Muzaffer Keklik, Salih Levent Çınar, Rıza Şimşek, Leylagül Kaynar
{"title":"A Case of Rapidly Progressing Tumoral-Stage Mycosis Fungoides","authors":"Muzaffer Keklik, Salih Levent Çınar, Rıza Şimşek, Leylagül Kaynar","doi":"10.4274/tjh.galenos.2024.2024.0298","DOIUrl":"10.4274/tjh.galenos.2024.2024.0298","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"291-292"},"PeriodicalIF":1.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dilemmas in the Diagnosis and Management of CML in Pakistan 巴基斯坦 CML 诊断和管理的困境。
IF 1.5 4区 医学
Turkish Journal of Hematology Pub Date : 2024-12-02 Epub Date: 2024-10-08 DOI: 10.4274/tjh.galenos.2024.2024.0280
Sahrish Khan, Muhammad Farooq Sabar, Mariyam Akbar, Abdul Waris
{"title":"Dilemmas in the Diagnosis and Management of CML in Pakistan","authors":"Sahrish Khan, Muhammad Farooq Sabar, Mariyam Akbar, Abdul Waris","doi":"10.4274/tjh.galenos.2024.2024.0280","DOIUrl":"10.4274/tjh.galenos.2024.2024.0280","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"286-287"},"PeriodicalIF":1.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信